Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate CAS:328086-60-8

Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate inoshandiswa senzira yakakosha yekugadzira peptide derivatives uye mishonga. Mapoka ayo anoshanda uye stereochemistry inopa mukana wekuwana mapeptide akaomarara uye peptidomimetics ane mukana wekuita bioactivity uye senge mishonga. Vatsvaguri vanoshandisa maumbirwo ayo ekuumba kuti vaunze amino acid residues uye heterocyclic moieties mu peptide sequences, vachichinja mashandiro avo ehupenyu uye chinangwa chaicho. Iyi compound inowana mashandisirwo mu peptide chemistry, uko inoshanda sechivako chekugadzira peptide, solid-phase peptide assembly, uye peptide drug design. Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate inogonesa kuvaka maraibhurari epeptide, peptide mimetics, uye peptide-based therapeutics inotarisa nzira dzakasiyana dzehupenyu uye mamorekuru. Basa rayo mukugadzirisa nekugadzirisa peptide rinobatsira mukugadzirwa kwemishonga mitsva, kuongororwa, uye maturusi ebiochemical. Muindasitiri yemishonga, Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate inoshandiswa mukugadzirwa kwemishonga yepeptidic, peptide conjugates, uye peptide-based prodrugs. Kubatanidzwa kwayo mukutsvaga peptide uye kuwanikwa kwemishonga kunogonesa kutsvaga peptide-mediated signaling, receptor interactions, uye therapy interventions munzvimbo dzakadai se oncology, immunology, uye neurology. Nekubatanidza iyi compound mu peptide structures, masayendisiti anogona kuwedzera pharmacokinetic properties, biological stability, uye target affinity ye peptide-based pharmaceuticals, kuwedzera spectrum ye peptide therapeutics uye mishonga yakasarudzika.